| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5825986 | Current Opinion in Pharmacology | 2015 | 6 Pages |
Abstract
This review will focus on autoimmunity, probably the field that benefited most from these new biological therapies that very significantly impacted the modalities of patient's care. The aim is to present the agents which constitute major disease modifying drugs for the treatment of chronic invalidating autoimmune diseases. In doing so, we shall distinguish between agents that globally depress immune responses and those that may selectively target the harmful autoimmune response over long-term while preserving the capacity of the host to react normally to exogenous antigens, in other words, agents promoting 'operational tolerance'.
Related Topics
Life Sciences
Neuroscience
Cellular and Molecular Neuroscience
Authors
Lucienne Chatenoud,